Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cingulate Inc ( (CING) ) has provided an announcement.
On May 13, 2025, Cingulate Therapeutics, a subsidiary of Cingulate Inc., terminated a grant agreement with a private family foundation, which had been established on April 8, 2025. The termination resulted in no financial obligations for Cingulate, and all prospective royalty obligations related to the commercialization of CTx-2103 were nullified. The company plans to continue the development of CTx-2103 in the third quarter of 2026, following the anticipated launch of its lead asset, CTx-1301, pending FDA approval.
The most recent analyst rating on (CING) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Cingulate Inc. operates in the pharmaceutical industry, focusing on the development of innovative drug products. Its primary products include CTx-1301 and CTx-2103, with a market focus on addressing unmet medical needs.
Average Trading Volume: 94,381
Technical Sentiment Signal: Sell
Current Market Cap: $16.9M
See more data about CING stock on TipRanks’ Stock Analysis page.